These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24292632)

  • 1. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.
    Jeong W; Rapisarda A; Park SR; Kinders RJ; Chen A; Melillo G; Turkbey B; Steinberg SM; Choyke P; Doroshow JH; Kummar S
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):343-8. PubMed ID: 24292632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.
    Jeong W; Park SR; Rapisarda A; Fer N; Kinders RJ; Chen A; Melillo G; Turkbey B; Steinberg SM; Choyke P; Doroshow JH; Kummar S
    Invest New Drugs; 2014 Apr; 32(2):340-6. PubMed ID: 24242862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.
    Kummar S; Raffeld M; Juwara L; Horneffer Y; Strassberger A; Allen D; Steinberg SM; Rapisarda A; Spencer SD; Figg WD; Chen X; Turkbey IB; Choyke P; Murgo AJ; Doroshow JH; Melillo G
    Clin Cancer Res; 2011 Aug; 17(15):5123-31. PubMed ID: 21673063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth.
    Greenberger LM; Horak ID; Filpula D; Sapra P; Westergaard M; Frydenlund HF; Albaek C; Schrøder H; Ørum H
    Mol Cancer Ther; 2008 Nov; 7(11):3598-608. PubMed ID: 18974394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma.
    Borsi E; Perrone G; Terragna C; Martello M; Dico AF; Solaini G; Baracca A; Sgarbi G; Pasquinelli G; Valente S; Zamagni E; Tacchetti P; Martinelli G; Cavo M
    Oncotarget; 2014 Apr; 5(7):1779-92. PubMed ID: 24732040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
    Sapra P; Kraft P; Pastorino F; Ribatti D; Dumble M; Mehlig M; Wang M; Ponzoni M; Greenberger LM; Horak ID
    Angiogenesis; 2011 Sep; 14(3):245-53. PubMed ID: 21452059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.
    Bianchini D; Omlin A; Pezaro C; Lorente D; Ferraldeschi R; Mukherji D; Crespo M; Figueiredo I; Miranda S; Riisnaes R; Zivi A; Buchbinder A; Rathkopf DE; Attard G; Scher HI; de Bono J; Danila DC
    Br J Cancer; 2013 Nov; 109(10):2579-86. PubMed ID: 24169353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
    Borsi E; Perrone G; Terragna C; Martello M; Zamagni E; Tacchetti P; Pantani L; Brioli A; Dico AF; Zannetti BA; Rocchi S; Cavo M
    Exp Cell Res; 2014 Nov; 328(2):444-55. PubMed ID: 25257607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages.
    Talks KL; Turley H; Gatter KC; Maxwell PH; Pugh CW; Ratcliffe PJ; Harris AL
    Am J Pathol; 2000 Aug; 157(2):411-21. PubMed ID: 10934146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors.
    Sobhanifar S; Aquino-Parsons C; Stanbridge EJ; Olive P
    Cancer Res; 2005 Aug; 65(16):7259-66. PubMed ID: 16103077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATR controls cellular adaptation to hypoxia through positive regulation of hypoxia-inducible factor 1 (HIF-1) expression.
    Fallone F; Britton S; Nieto L; Salles B; Muller C
    Oncogene; 2013 Sep; 32(37):4387-96. PubMed ID: 23085754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia.
    Sun HL; Liu YN; Huang YT; Pan SL; Huang DY; Guh JH; Lee FY; Kuo SC; Teng CM
    Oncogene; 2007 Jun; 26(27):3941-51. PubMed ID: 17213816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
    Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
    Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma.
    Wu J; Contratto M; Shanbhogue KP; Manji GA; O'Neil BH; Noonan A; Tudor R; Lee R
    World J Clin Oncol; 2019 Mar; 10(3):149-160. PubMed ID: 30949444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
    Xia Y; Choi HK; Lee K
    Eur J Med Chem; 2012 Mar; 49():24-40. PubMed ID: 22305612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
    Dean E; Jodrell D; Connolly K; Danson S; Jolivet J; Durkin J; Morris S; Jowle D; Ward T; Cummings J; Dickinson G; Aarons L; Lacasse E; Robson L; Dive C; Ranson M
    J Clin Oncol; 2009 Apr; 27(10):1660-6. PubMed ID: 19237630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers.
    Shi M; Guo XT; Shu MG; Chen FL; Li LW
    Med Hypotheses; 2007; 69(1):33-5. PubMed ID: 17280792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural antisense transcripts of hypoxia-inducible factor 1alpha are detected in different normal and tumour human tissues.
    Rossignol F; Vaché C; Clottes E
    Gene; 2002 Oct; 299(1-2):135-40. PubMed ID: 12459261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition.
    Choi H; Chun YS; Kim SW; Kim MS; Park JW
    Mol Pharmacol; 2006 Nov; 70(5):1664-71. PubMed ID: 16880289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo bioluminescence imaging monitoring of hypoxia-inducible factor 1alpha, a promoter that protects cells, in response to chemotherapy.
    Viola RJ; Provenzale JM; Li F; Li CY; Yuan H; Tashjian J; Dewhirst MW
    AJR Am J Roentgenol; 2008 Dec; 191(6):1779-84. PubMed ID: 19020250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.